The SwissSarcomaNetwork aims at improving and ensuring the quality of sarcoma patient care in Switzerland.
Sarcomas belong to the rare cancers, representing about 1% of all malignant tumors and showing a wide variety of histologically as well as biologically different entities. Long term outcome is largely depending on consistent diagnostic and therapeutic concepts involving all specialities. Worldwide, up to half of the sarcoma patients are not managed according to established clinical guidelines which has considerable impact on long term outcome. In the last years, efforts to improve outcome have been directed towards centralization of care, hereby assuming that volume equals expertise, availability of best technical equipment and hence quality. This centralization approach strongly reflects the view of the health care system and to a far less extent the process from the patient’s first presentation with symptoms until the end of sarcoma multimodal therapy and beyond. For reasons such as mountainous geography, four different main languages and the reluctance of patients to move and travel far, Switzerland has many hospitals within short distances which are more or less independently organized within 26 cantons/counties. Because of these conditions, sarcoma experts are working in many different institutions. For the present time, only a minority is organized within dedicated treatment networks and hence does not follow established guidelines for the management of sarcoma patients. Even in regions with a high density of medical services, insufficiently planned excisions of a lump, on histological work up turning out to be a sarcoma, occur in more than 20%. Furthermore, sarcoma surgery is subdivided into anatomical regions, for instance visceral, thoracic or orthopedic, as well as the tissue of tumor origin such as bone or soft tissue, although they all share the same biological background. Children and adolescents traditionally have been cared for by pediatric oncologists, in Switzerland provided by one of the 9 SPOG centers (Swiss Pediatric Oncology Group) building the network of pediatric oncology in Switzerland. No institutionalized settings exist for the special group of young adults although there is enough evidence that not only tumor biology is different compared to later in life but also their special needs are not fully met in adult oncologies. Taken all these facts together, it is obvious that sarcoma expertise must not be attributed to one single person, discipline or even institution. The complexity of the management of a sarcoma patient is far too complex and requires close collaboration of all involved disciplines on an equivalent background.
In order to improve and ensure the quality of the entire process in the management of a sarcoma patients - right from the first symptoms to the end of multimodal and multidisciplinary treatment and even beyond - we feel to rethink and reorganize our current approach of sarcoma treatment and to define clinical practical guidelines to be followed by all sarcoma care givers.p>Instead of institutions keeping on fighting for patient numbers, sarcoma experts from all interested institutions are invited to work together in the frame of a national network in order to continuously share, exchange and improve their experience and knowledge and define diagnostic and therapeutic pathways to be followed by all care givers. Decisions on procedures and management will then no longer be depending on the opinion of one person only. We therefore do believe that the constitution of a «network of excellence» may represent an indispensable alternative to the currently ongoing unsatisfying geographic centralization efforts that do not meet all the complex needs and concerns in the comprehensive management of sarcoma patients of all age groups.
For all these reasons, we establish the SwissSarcomaNetwork to bring sarcoma experts together across and beyond institutions in Switzerland.
The main objective of the SwissSarcomaNetwork is to improve and ensure the quality of sarcoma patient care in Switzerland.
- To foster inter-institutional and interdisciplinary sarcoma care roadmaps covering the complete patients pathway from the first presentation to the end of treatment and follow up care for pediatric, adolescent and adult patients with malignant bone and soft tissue tumors, independent of anatomical sites.
- To improve the quality of sarcoma patient care, through continued education, teaching and research thereby establishing educational policies.
- To build the sarcoma service platform, to strengthen and provide sarcoma competence in Switzerland for pediatric, adolescent and adult patients through close cooperation among all participating institutions .
- To establish diagnostic and clinical pathways including binding recommendations und requirements for all diagnostic and therapeutic modalities.
- To establish a prospective sarcoma data base (registry) enabling the network to foster research projects and to become an attractive international partner for collaborations both on clinical trials as well as research projects.
- To establish a quality assurance system on outcome and comprehensive care processes.
- To run a weekly tumor board, the SwissSarcomaBoard, to interdisciplinarily and interinstitutionally define risk-adapted, patient-focused pre- and post-treatment strategies for each sarcoma patient across Switzerland.
- Shared care by interinstitutional exchange of specialized surgical experts in their field.
- To establish and maintain a prospective sarcoma data base (registry) by web-based access.
- To define and ensure indicators for quality of care of all sarcoma patients.
- To establish a quality assurance system on outcome and comprehensive care processes.
- To establish educational policies comprising teaching, research and organization of continuous education events in the field.
The mission of the SwissSarcomaNetwork is to provide excellent quality of sarcoma patient care in Switzerland. To achieve this, international embedding of the SwissSarcomaNetwork (SSN) is of the utmost importance, to foster not only the medical exchange to set, review and improve the highest possible quality of care in Switzerland, but also to team up with other well established international networks. For these reasons, we have established an International Advisory Board of Sarcoma Experts.
The missions of the International Advisory Board for the SSN include:
- to provide second opinions for patients being discussed at the SwissSarcomaBoard
- to support the establishment of Sarcoma Guidelines (based on ESMO and existing Swiss Guidelines) as well as good clinical practice standards within the SSN
- to support the implementation and the use of the SwissSarcomaRegister to define quality sarcoma care
- to provide yearly instructional course lectures in their domain
- to act as advisor for the establishment of a E-learning tool.
The international Sarcoma Advisory Board of the SSN represents an international group of world renowned experts in the sarcoma discipline, and includes the following experts:
Prof. Javier Martin-Broto
Founder & Vice-President GEIS (Spanish Group for Research on Sarcomas)
Founder & Consortium Coordinator SELNET (Sarcoma European LatinAmerican Network)
Prof. Alessandro Gronchi
Chair Soft Tissue Sarcoma Committee of the Italian Sarcoma Group (ISG)
President of Italian Society of Surgical Oncology
Past-Chair of EORTC Soft tissue and Bone Sarcoma Group
Past-President of CTOS
Founder of Trans-Atlantic Retro-Peritoneal Sarcoma Working Group (TARPSWG)
The Swiss Sarcoma Network
The need to establish an interdisciplinary sarcoma platform to foster the exchange among sarcoma experts in Switzerland was recognized in 2013, when the «Gesundheitsdirektorenkonferenz» (GDK) re-organized the treatment of pediatric sarcoma patients. To support this process, the Swiss National Sarcoma Advisory Board (SNSAB) – initially a loose national association of sarcoma interested physicians - was concurrently established to define clinical practice guidelines for the treatment and work-up of sarcoma patients, to guide collaboration between sarcoma centers and other hospitals and to set up a cohort study. The newly established SNSAB has proven to be appreciated and successful which lead to the mandate by IV-HSM in 2016 to elaborate a concept how to organize sarcoma care in Switzerland.
However, this process was then suspended mainly for a lack of manpower capacity on part of IV-HSM to push this process further, but also because the SNSAB was only constituted of interested individuals and not of representatives of institutions and societies.
Particularly in sarcoma treatment, interdisciplinary cooperation is the key to success. For instance, surgical resections of large sarcomas require the collaboration of the orthopedic and/or visceral surgeon with plastic or vascular surgeons. Therefore, to integrate both, the institutional requirements and the interdisciplinary exchange of sarcoma experts, the SwissSarcomaNetwork (as a society) was founded to address these key requirements to meet the mission and objectives as outlined above.
The SwissSarcomaNetwork is the new nationwide platform of several institutions determined to close collaboration of their sarcoma experts as well as their institutional representatives (please compare SwissSarcomaBoard).
The Swiss Federal Institute of Intellectual Property (www.ige.ch) has registered the brand SwissSarcomaNetwork with the number 742190 into the brand-registry as of January 30, 2020.
The society is an institutionalized platform to organize sarcoma care, research and education on a national level. It commits to the following statutes:
The society SwissSarcomaNetwork aims to foster the interinstitutional and interdisciplinary work-up, treatment and follow-up care of all patients with bone and soft tissue tumors (specifically sarcomas) by concentration of competence, education and research as well as ressources. The main objective is to improve and ensure quality of care and patient outcome.
The society organizes the SwissSarcomaBoard and maintains a data registry, through which patient outcome is assessed by indicators of quality, to improve transparency both for patients and legal body/health care authorities, and to organize research projects and collaborations with international partners.
In the following link, you find a suggestion for the statutes.
The following links provide an overview on the organisation incl. statutes and organigram.
The The SwissSarcomaNetwork is open for all institutions to participate. Prerequisite is the commitment to the missions and objectives, and active participation.
Each participating institution is member of the society «Trägerverein», which runs the SwissSarcomaNetwork.
An institution determines an institutional representative (which may be a physician or the CEO) who together represent the Board of the society, as well as their clinical experts.
All the institutional representatives and all the clinical sarcoma experts constitute the members of the SwissSarcomaNetwork. They elect the Board members of the network and as well as its chair.
- Committment to live up for the missions and objectives - summarized in the statutes - of the society.
- Represent all consecutive sarcoma patients at the SwissSarcomaBoard.
- Treat patients according to good clinical practice guidelines as well as standard operating procedures (SOP).
- Provide clinical data into web-based ANQ-registry, after obtaining informed consent from patients.
- Yearly fee depending on the number of delegates, which is determined by the Board of the society.
At the launch of the SwissSarcomaNetwork, seven institutions from the German part of Switzerland committed to participate and live up to the mission and objectives, including both pediatric and adult hospitals, as well as University hospitals, major supra-regional center based hospitals and cantonal hospitals.
The Swiss Sarcoma Board
The SwissSarcomaBoard as integral part of the SwissSarcomaNetwork is uniting sarcoma specialists from all disciplines and from all over Switzerland to discuss and determine the work-up, treatment strategies and follow-up care for children, adolescents and adult patients with bone and soft tissue tumors.
The SwissSarcomaBoard establishes and ensures clinical practice guidelines, standard operating procedures, organizes the weekly Sarcoma Board meeting, as well as the yearly Swiss Sarcoma Symposium.
The SwissSarcomaBoard is responsible for teaching and research. It makes a commitment to foster education not only for the experts, but also for young colleagues and students, to carry on excellence also in the future.
The SwissSarcomaBoard meeting takes place every Tuesday at 5 o'clock. There are meeting rooms in Basel, Bellinzona, Chur, Luzern and Winterthur. These meeting rooms are connected via Telemedicine (provided by ActVisual), and every one involved in patient treatment or part of the network can log in to follow and participate the discussion.
Who can present? And how do I do it?
Everyone who is involved in patient care or has a patient with the suspicion of sarcoma can log in. To log in, please go to https://ksw.myhealthcare.ch/join/mXts5SXFFO and download the software.
Importantly, registration is required. Send an email to to get the access code.
How to present a patient?
To present a case, it is important to follow the SOPs established by the network.
The following specialists listed across the disciplines represent the members of the SwissSarcomaBoard and thereby constitute the SwissSarcomaService.
Pathologie Enge Zürich
Prof. Dr. med.
Thoracic - Surgery
Good Clinical Practice (GCP) - Guidelines
- Minimal work-up requirements
- Biopsy of soft tissue sarcomas
- Sequence of therapy
- Surgical Guidelines: Extremity
- Surgical Guidelines: Retroperitoneal
- How to deal with whoops surgery
- Radiation Therapy Guidelines
- Radiation Therapy Guidelines: Addendum
- Sarcoma Radiation During Covid-19 Pandemic
- Chemotherapy Guidelines (Weichteilsarkome)
- Chemotherapy Guidelines (Knochentumore)
- Follow-up Guidelines
- Why preoperative Radiation Therapy is preferred?
- Combination Therapy (Sequence of radiation therapy and Surgery)
- How to Manage Lipomatous Tumors
- How to Manage Chondrogenic Lesions
Standard Operating Procedures (SOP)
A. Sarcoma Board Meeting
- HSM recommendations for a HSM-Tumorboard.
This information summarizes the recommendations for a tumorboard by the HSM-Fachorgan.
- How to register a patient for the SwissSarcomaBoard Meeting?
This information summarizes the information which needs to be entered to register a patient.
- Registration form SwissSarcomaBoard Meeting.
The form to be filled out for registering a patient for the meeting.
- What the protocol of the SwissSarcomaBoard Meeting includes?
This information summarizes the information which being sent to all involved physicians.
B. Reporting Medical Analysis of Procedures
- How to conduct MRI imaging.
This link provides the necessary sequences/protocol how to conduct an MRI to optimally visualize a lesion.
How to report imaging analyses (first time consultation).
- How the pathologist works-up a resected tumor specimen?
This link provides how a resected tumor specimen is worked up by the pathologist to define margins and allow further analyses.
- How to report pathology analyses.
This link provides a recommendation on how to report an pathology analyses.
- How to report on a surgical procedure.
This information summarizes the information which needs to be reported by the surgeon.
- How to report on radiation oncology therapies.
This information summarizes the information which needs to be reported by the radiation oncologist.
- What to report on a systemic therapy.
This information summarizes recommendation which may be reported by the medical oncologist.
How to report imaging analyses (follow-up consultation).
These links provide a suggestion how to structurally analyze imaging for bone- and soft tissue analysis.
C. Outpatient Consultations
- How to organize your consultation.
This link may be used to plan consultations for the secretary and the entire team.
- What to assess at 1st time surgical consultation.
This links may be used to plan consultations fort he secretary and the entire team.
- What to asses at a follow-up surgical consultation.
This information may be used to help collecting informations during consultations.
- Data Exchange
This links summarizes how the data in the registry are collected, shared and reported.
Over the last few decades, the outcome of sarcoma patients has plateaued, and despite being extremely active with great technical progress, real advancement has been scarce overall. Many reasons do account for this though, but we definitely must do better.
To improve the quality of patient care, we first need to better define and know what we treat; second, we need to follow it up to understand what the consequence of our acting was. For this purpose, we need to register critical data to assess the quality of our patient care. Equally important, we need to structurally better assess our day to day data assessment, so that all involved sarcoma experts speak the same language (eg, everyone must have the same definition regarding an R1 margin etc.). Through this effort, we will be able to assess how many patients with which pathology are treated in our network, how their treatment was conducted, and what the outcome was. This assessment of quality is not only important towards our patients, but also towards legal bodies in Switzerland, and last but not least, is an important prerequisite to become a partner for international collaborations and networks.
We define the indicators of quality to minimally include: exact WHO diagnosis, type of treatments, date of local or systemic recurrences, as well as follow-up informations. Further also: number of unplanned excisions (whoops), biopsy taken by the surgeon-radiologist-team, central review of pathology, discussion at sarcoma board before and after surgery, surgical margin status, surgery performed by dedicated sarcoma surgeon, was decision of sarcomaboard carried out, status of disease at last contact.
The SwissSarcomaNetwork elected to collaborate with Adjumed, of which the AQC (Arbeitsgemeinschaft für Qualitätsicherung in der Chirurgie) project is the largest with more than 1.5 Mio datasets and more than 20 years of experience.
Adjumed bases their support on three columns: collection, analysis and validation of data. Adjumed adjusts the webbased data collection to the needs of the user, thereby also superimposing their wealth of datasets available. The analysis of data is made possible for all combinations of parameters; the validation includes direct patient contact to obtain regular information.
Under the BASEC-NR. 2019-01107, the cantonal ethic commission has approved the application of the SwissSarcomaNetwork for the study: Development of an outcome prediction for patient selection in sarcoma care.
According to the HFV of Swiss Federal law, the approval of this research project allows the assessment patient related clinical data as well as biological material, retroactive until January 2005, within the members of the SwissSarcomaNetwork.
This study is listed under www.clinicaltrials.gov.
Sarcomas belong to a heterogenic group of mesenchymal tumors affecting either soft tissues (common), or bones (rare lesions). The differential diagnosis of sarcomas is often difficult due to the general rarity of this tumor group compared to epithelial of hematologic tumors on one hand, and to the large number of entities with partially overlapping histopathologic properties on the other. Recent years led to deepened understanding of the complex genetic background of mesenchymal neoplasia and widening of the spectrum of diagnostic pathologic tools allowing better definitions and identification of individual tumor subtypes.
The recently published (early 2020), currently valid WHO Classification of Soft Tissue and Bone Tumors lists over 100 tumor entities including variants, often characterized by specific genetic aberrations, which can be detected by molecular diagnostic studies.
Establishing the precise tissue diagnosis of a soft tissue or bone tumor is of immense importance for the choice of the correct treatment strategy for every patient. The histologic diagnostics of sarcomas must be performed by experienced pathologists, who are involved in sarcoma diagnostics on a daily basis and who have access to auxiliary studies.
It is well documented in the literature that the incorrect histopathological diagnosis may lead to the initiation of false therapy with severe deleterious consequences for the affected patient. Due to rarity of soft tissue and bone tumors and inherent difficulties in their understanding and diagnostics, the discrepancies in expert opinion may vary from the initial histopathologic diagnosis in up to one third of cases. Mandatory systematic review of all of the diagnoses by reference pathology as well as regular correlation of histopathologic findings with clinical situation and imaging during multidisciplinary tumor boards ensures the correctness of the histopathological diagnostics.
Requests for second opinion of biopsy samples of soft tissue and bone tumors:
- Submission of all histological slides and at least one representative paraffin block.
- Full written documentation, incl. original histological reports.
The reference pathology review of biopsy material of the patients referred to the Swiss Sarcoma Network (SSN) is coordinated by Prof. Beata Bode-Lesniewska, an experienced pathologist with many years of expertise in histopathology of mesenchymal neoplasia, in collaboration with the Working Group on Sarcoma (WGS) of the Swiss Society of Pathology (SSPath).
Current biopsy material of all patients listed for sarcoma board is either directly diagnosed by, or reviewed by reference pathology on a weekly basis. The histopathological results of individual patients are presented every week during the sarcoma board. The concurrent referral of the patient for the discussion in sarcoma board and initiation of the reference review of histopathological diagnoses at the same time ensures the quality of the pathologic diagnoses and prevents delays in decision making on the patient management.
The quality of the histopathological diagnoses of the SSN patients is reviewed and analysed biannually by the WGS group of the Swiss Society of Pathology (SSPath).
Requests for second opinion of biopsy samples of soft tissue and bone tumors:
- Submission of all histological slides and at least one representative paraffin block.
- Full written documentation, incl. original histological reports.
Several working groups related to various topics of pathological diagnostics are organized by the Swiss Society of Pathology (SSPath). Regarding sarcoma, there are a soft tissue and bone working group. Working Group on Sarcoma (WGS) of the SSPath is an active group of pathologists from many different Swiss institutes, who are interested in soft tissue mesenchymal neoplasia and meet biannually since 1990-ies, coordinated originally by Prof. Gernot Jundt (University Hospital Basel). Prof. Beata Bode-Lesniewska has been organizing the WGS meetings since 2003. The multidisciplinary (incl. radiologists) Swiss Bone Club of the Bone Tumor Referral Center in Basel, the corresponding bone working group on sarcomas of the SSPath, is organized by Prof. Daniel Baumhoer, and meets also twice yearly.
The participants of the meetings of the Working Group on Sarcoma (WGS) discuss the new developments in our understanding of mesenchymal tumors based on interesting case examples submitted by its members. The histopathological diagnoses of the sarcomas of the SSN patients are retrospectively reviewed with deepened discussion on unclear findings.
Research And Education
The SwissSarcomaNetwork is committed to provide excellent education on each level. For this purpose, it establishes an International Advisory Board, conducts the Swiss Sarcoma Symposium, and organizes the Sarcoma Knowledge Update as well as the Sarcoma Guidelines Update.
The SwissSarcomaNetwork is committed to improve excellence through research. This entails clinical, translational as well as basic research. Patient related research builds on our register which is key to identify all necessary information for all aspects of research. One of the main goals is to conduct these research studies with international collaborators.
The SwissSarcomaNetwork is committed to provide education on a broad level. It organizes the following public events.
The Swiss Sarcoma Symposium
The SwissSarcomaSymposium is being held in Lucerne in May 2020. It brings together the International Advisory Board, experts from the Mayo clinic as well as Swiss Sarcoma experts. This years topics include the organization of networks & quality indicators to share among the sarcoma community. Another topic focuses on an expert panel discussion of unsolved questions the management of patients with soft tissue sarcomas. Further, the implementation of an international hemipelvectomy registry will be discussed.
The Swiss Sarcoma Knowledge Update
The SwissSarcomaSymposium organizes meetings at the SwissSarcomaSymposium institutions together with the International Advisory Board every 3-4 months. A topic will be determined at the preceding meeting, and all sarcoma experts are invited.
The Swiss Sarcoma Guidelines & Registry Update
During these quarterly meetings, general and specific topics of current sarcoma care practice will be discussed, revisited and updated if necessary. At the same time, the registry items will be continuously discussed and updated.
Preceptorships at the Sarcoma Centers of the International Advisory Board
The SwissSarcomaSymposium provides the opportunity to visit the sarcoma centers in Paris, Lyon, Sevilla and Milano, for continued education of sarcoma experts.
The SwissSarcomaSymposium provides the opportunity to attend the SB also via Telemedicine, thereby offering the exposure to some 250 new malignant diagnoses, and nearly 1000 overall presentations per year.
Training of Future Sarcoma Experts
The SwissSarcomaSymposium is committed to advance the science and to train our future sarcoma experts, to provide excellent future sarcoma care also in the future.
The SwissSarcomaNetwork’s clinical research bases on the philosophy of transparent assessment and sharing of data in the registry.
Because the SwissSarcomaNetwork registry was built up based on the most widely used registries worldwide such as French registry, the Toronto PMH sarcoma database, and TARPSWG registry, the SELNET registry as well as the NSQIP Pediatric sarcoma analysis. As such, international exchange is possible, and through data sharing, large international numbers are available to address key questions.
One main focus is the definition, development and assessment of quality indicators (QI) of sarcoma patient care. Together with the International Board of the SSN, currently 18 QI were defined - which are continuously updated - and being assessed through the registry. As such, benchmarking will be possible for international comparison.
Because the interdisciplinary SwissSarcomaNetwork registry combines the data assessment for each discipline separately, it allows the comparison of each single parameter among the disciplines, with registering the basic data only once and thereby allowing a transdisciplinary outcome analysis.
The SwissSarcomaNetwork is committed to invest into translational and basic research through international collaboration.
The SwissSarcomaNetwork is establishing the collaboration with SELNET (Sarcoma European LatinAmerican NETwork), which under the European Horizon2020 Call: (H2020-SCI-BHC-2018-2020), has established a sarcoma biobank, translational research projects, preclinical sarcoma models as well as translational studies.
The SwissSarcomaNetwork has a strong commitment to conduct and support clinical trials. Currently, it mainly collaborates with SAKK and SELNET.
SAKK, the Swiss Group for clinical cancer research, has currently 2 open trials on
- NAPAGE: Nab-paclitaxel and gemcitabine for advanced soft tissue sarcomas (SAKK 57/16)
- Patients with metastasized soft tissue sarcoma: Quality of life under chemotherapy or pazopanib treatment (GISG11, PazoQoL)
SELNET specifically under the auspices of the Spanish (GEIS), French and Italian sarcoma networks, have a longstanding history of very successful conductance of clinical trials. Currently, SELNET establishes the following clinical trials regarding perioperative therapy on
- breast sarcoma
- uterine sarcoma
- Reconstruction of the flexor compartment after soft tissue sarcoma resection of the proximal forearm
- Complete anterior pubic hemipelvectomy does not require reconstruction
- Giant pendulum wdls through sciatic notch: transient iliac osteotomy for complete tumor resection
- Toxic megacolon with perforation as a severe complication after sacro-iliac hemipelvectomy
- Osteotomy through the sacral ala: the advantage of using a 3d-printed resection guide
- Is total humerus prosthetic reconstruction safe in a patient with pathological fracture from dedifferentiated chondrosarcoma?
- Extra-articular PAO resection en-bloc with the proximal femur and reconstruction with a pelvis tumor-prosthesis
- Low demand hanging bridge reconstruction after Tikhoff-Linberg shoulder resection
- High demand 3d-printed custom made shoulder prosthesis reconstruction after Tikhoff-Linberg resection
- Excessive white drainage after cerament filling and curettage of an aneurysmal bone cyst at the distal radius
- Aggressive juxtacortical chondromyxoid fibroma of the proximal thigh requiring complete proximal femoral resection
- Complete resection of the obturator internus muscle through antero-inferior pelvic exposure
- Extended forequarter resection including the chest wall and lung with brachial free fillet flap coverage
Studer G, Hofer S, Treumann T, Schweiwiller A, Bode-Lesneiwska B, Diebold J, Fuchs B:
Information zum überregionalen Schweizerischen Sarkom-Netzwerk (SSN)
Luzerner Arzt 2019:(118) 56-59
Studer G, Treumann T, Hofer S, Bode B, Fuchs B:
Work-up und präoperative Radiotherapie bei Weichteilsarkomen des Erwachsenen
Schweizer Krebsbulletin, Band 39, Juni 2019, Seiten 121-124
Qualitätssicherung in der Behandlung von Sarkomen: Eine interdisziplinäre und interinstitutionelle Herausforderung. Editorial
Schweizer Krebsbulletin, Band 39, Juni 2019, Seiten 99-101
Bode-Lesniewska B, Fritz C, Exner GU, Wagner U, Fuchs B:
EWSR1-NFATC2 and FUS-NFATC2 Gene Fusion-Associated Mesenchymal Tumors: Clinicopathologic Correlation and Literature Review
Rupp NJ, Bode B, Broglie MA, Morand GB:
Kaposi Sarcoma of the Ear in HIV-Negative Patients
Head Neck Pathol. 2019;13(2):255-6
Opitz I, Lauk O, Schneiter D, Ulrich S, Maisano F, Weder W, et al:
Intraluminal EWSR1-CREB1 gene rearranged, low-grade myxoid sarcoma of the pulmonary artery resembling extraskeletal myxoid chondrosarcoma (EMC)
Arlt MJ, Kuzmanov A, Snedeker J, Fuchs B, Silvan U, Sabile A:
Fascin-1 enhances experimental osteosarcoma tumor formation and metastasis and is related to poor patient outcome
BMC Cancer 19(1):83, 2019
CORR Insights: Micrometastatic Drug Screening Platform Shows Heterogenous Response to MAP Chemotherapy in Osteosarcoma Cell Lines
Clin Orthop Rel Res 476(7):1412-1414, 2018
Wilburger JCF, Kettelhack C, Fuchs B, Schaefer DJ, Osinga R:
Giant Myxoid Liposarcoma of the Gluteal Region: Case Report of Patient Caused Delay of Surgical Treatment ad Review of the Literature
J Surg Case Rep. doi:10.1093, Oct 08, 2018
Studer G, Glanzmann C, Maduz F, Bode B, Fuchs B:
Preoperative IMRT for Softtissue Sarcoma of the Extremities and Trunk: Low Rate of Wound Complications
Current Orthopaedic Practice 29(5):466-470, 2018
Fuchs B, Krieg A, Kettelhack C, Studer G, Bode B, and the SwissSarcomaNetwork:
Behandlung von Primären Knochentumoren am Becken
InFo Onkologie Hämatologie 8-12, 2018 (Medizinonline.ch)
Fuchs B, Krieg A, Kettelhack C, Bode B, Studer G, and the SwissSarcomaNetwork:
Sakropelvine Osteotomie für die Typ-I-Resektion von Knochentumoren am Becken
Leading Opinions Orthopädie & Rheumatologe 4:70-73, 2018
Velz J, Agaimy A, Frontzek K, Neidert MC, Bozinov O, Wagner U, et al:
Molecular and Clinicopathologic Heterogeneity of Intracranial Tumors Mimicking Extraskeletal Myxoid Chondrosarcoma
J Neuropathol Exp Neurol. 2018;77(8):727-35
Hodel S, Laux C, Farei-Campagna J, Bode-Lesnievska B, Müller DA:
Impact of biopsy sampling errors and quality of surgical margins on local recurrence and survival in chondrosarcoma
Cancer Management and Research 2018
Arteau A, Fuchs B:
Complete Deltoid Resection in Infancy results in Normal Shoulder Function at Longterm Followup
J Medical Case Reports 11(1):13, 2017
Meier D, Botter S, Campanile C, Robl B, Gräfe S, Pellegrini G, Born W, Fuchs B:
Foscan and Foslip based Photodynamic Therapy in Osteosarcoma in vitro and in Intratibial Mouse Models
International J Cancer Dec 10 2016 doi:10.1002/jc.30572
Robl B, Botter SM, Boro A, Meier D, Neri D, Fuchs B:
Evaluation of F8-TNF-alpha in Models of Early and Progressive Metasttic Osteosarocma
Transl Oncol. 10(3):419-430, 2017
Neidert M, Leske H, Frontzek K, Bode B, Capper D, Regli L, et al:
A 49-year old female with multiple extra-axial tumors
Brain pathology. 2017;27(2):235-6
Moderne histopathologische Klassifikation und Klinik der Weichteiltumoren
Therapeutische Umschau. 2017;74(4):204-8
Boro A, Bauer D, Born W, Fuchs B:
Plasma Levels of MIRNA-155 as a Powerful Diagnostic Marker for Dedifferentiated Liposarcoma
Am J Cancer Res 6(2):544-52, 2016
Muff R, Botter S, Husmann K, Tchinda J, Selvam P, Seeli-Maduz F, Fuchs B:
Explant Culture of Sarcoma Patients' Tissue
Lab Invest DOI:10.1038 April 26, 2016
Neklyudova O, Arlt M, Brennecke P, Thelen M, Gvozdenovic A, Kuzmanov A, Robl B, Botter S, Born W, Fuchs B:
Altered CXCL12 Expression Reveals a DualRole of CXCR4 in Osteosarcoma Primary Tumor Growth and Metastasis
J Cancer Res Clin Oncol Epub ahead of print June 14 2016
Burger D, Pumberger M, Fuchs B:
An Uncemented Spreading Stem for the Fixation in the Metaphyseal Femur: A Preliminary Report Sarcoma May 15, 2016:7132838
Kumar R, Boro A, Fuchs B:
Involvement and Clinical Apsects of microRNA in Osteosarcoma: A Review
Int J Mol Sci 2016 Jun 3:17(6)
Gvozdenovic A, Boro A, Meier D, Bode-Lesniewska B, Born W, Muff R, Fuchs B:
Targeting αvβ3 and αvβ5 Integrins Inhibits Pulmonary Metastasis in an Intratibial Xenograft Osteosarcoma Model
Oncotarget 7(34):55141-55154, 2016
Robl B, Botter S, Pellegrini, Neklyudova O, Fuchs B:
Evaluation of Intraarterial and Intravenous Cisplatin Chemotherapy in the Treatment of Metastatic Osteosarcoma using an Orthotopic Xenograft Mouse Model
J Exp Clin Cancer Res 35(1):113, 2016
Jentzsch T, Vlachopoulos L, Fürnstahl P, Müller D, Fuchs B:
Tumor Resection at the Pelvis using Three-dimensional Planning and Patient-specific Instruments: A Case Series
World Journal of Surg Oncology 14(1):249, 2016
Scaglioni M, Lindenblatt N, Barth A, Fuchs B, Weder W, Giovanoli P:
Free Fillet Flap Application to Cover Forequarter or Traumatic Aputation on an Upper Extremity: A Case Report
Microsurgery 36(8):700-704, 2016
Wolpert F, Grotzer MA, Niggli F, Zimmermann D, Rushing E, Bode-Lesniewska B:
Ewing's Sarcoma as a Second Malignancy in Long-Term Survivors of Childhood Hematologic Malignancies
Cathomas R, Rothermundt C, Bode B, Fuchs B, von Moos R, Schwitter M:
RANK ligand Blockade with Denosumab in Combination with Sorafenib in Chemorefractory Osteosarcoma: a possible Step forward?
Oncology 88(4):257-60, 2015
Husmann K, Arlt M, Jirkof P, Arras M, Born W, Fuchs B:
Primary Tumour Growth in an Orthotopic Osteosarcoma Mouse Model Is Not Inflenced By Analgesic Treatment with Buprenorphine And Meloxicam
Laboratory Animals 49(4):284-93, 2015
Robl B, Pauli C, Botter S, Bode B, Fuchs B:
Prognostic Value of Tumor Suppressors in Osteosarcoma Before and After Neoadjuvant Chemotherapy
BMC Cancer 15(1):379- , 2015
Datta NR, Grobholz R, Puric E, Bode B, Lomax N, Khan S, Gaipl U, Fuchs B, Bodis S:
Enhanced Tumour Regression in a Patient of Liposarcoma Treated with Radiotherapy and Hyperthermia: Hint for Dynamic Immunomodulation by Hperthermia
Int J Hyperthermia 20:1-4, 2015
Boro A, Arlt M, Lengnick H, Robl B, Husmann K, Bertz J, Born W, Fuchs B:
Prognostic Value and in-vitro Biological Relevance of Neuropilin 1 and Neuropilin 2 in Osteosarcoma
Am J Translational Res 7(3):640-53, 2015
Jentzsch T, Fuchs B:
Therapie von Sarkomen
InFo@Onkologie&Hämatologie 3(5):1-6, 2015
Studer G, Brown M, Fuchs B:
Radiotherapie bei Weichteilsarkomen des Erwachsenen: Präoperative und Dosis-Volumen-konformierende Anwendung
InFo@Onkologie 2:13-15, 2015
Hodel S, Seeli F, Fuchs B:
Demographische Analyse von Patienten mit Osteosarkom, Chondrosarkom, Ewing’s Sarkom von einem Sarkomzentrum in der Schweiz
PRAXIS Schweizerische Rundschau für Medizin 104(13):673-80, 2015
Muff, Rath P, Kumar R, Husmann K, Born W, Baudis M, Fuchs B:
Genomic Instability of Osteosarcoma Cell Lines during Long-term in vitro Culture
PlosOne 10(5):e0125611, 2015
Kumar R, Fuchs B:
Hedgehog Signaling Inhibitors as Anti-cancer Agents in Osteosarcoma
Cancers 7(2):784-94, 2015
Kumar R, Arlt M, Robl B, Kuzmanov A, Neklyudova O, Husmann K, Born W, Fuchs B:
Sunitinib Malate (SU-11248) Reduces Intratibial Tumour Burden And Lung Metastasis In a Preclinical Mouse Model Of Osteosarcoma
Am J Cancer Res 5(7):2156-68, 2015
Husmann K, Ducommun P, Sabile A, Pedersen E, Born W, Fuchs B:
Signal Transduction and Downregulation of C-Met in HGF-stimulated Low and Highly Metastatic Human Osteosarcoma Cell Lines
Biochem Biophys Res Commun 464(4):1222-7, 2015
Swiss National Sarcoma Advisory Board: Vorstellung des Schweizer Konsensus
Leading Opinions Hämatologie&Onkologie 3(15):78-80, 2015
Müller D, Fuchs B:
Whoops Läsionen bei Weichteilsarkomen
InFo@Onkologie&Hämatologie 8:26-29, 2015
Ture M, Barth J, Angst F, Aeschlimann A, Schnyder U, Zerkiebel N, Perseus J, Renner C, Imesch P, Fuchs B, Huber G, Walt H, Martin-Soelch C, Jenewein J:
Use of Inpatient Rehabilitation for Cancer patients in Switzerland: Who undergoes Cancer Rehabilitation?
Swiss Medical Weekly December 4, 2015 DOI 10.4414/smw.2015.14214
Bredell M, Schucknecht B, Bode Lesniewska B:
Tenosynovial, diffuse type giant cell tumor of the temporomandibular joint, diagnosis and management of a rare tumor
Journal of clinical medicine research. 2015;7(4):262-6
Meier D, Campanile C, Botter S, Born W, Fuchs B:
Cytotoxic Efficacy of Photodynamic Therapy in osteosarcoma Cells in vitro
J Vis Exp 2014 Mar 18; (85). Doi:10.3791/51213
Brennecke P, Arlt M, Husmann K, Campanile C, Gvozdenovic A, D'Apuzzo T, Thelen M, Born W, Fuchs B:
CXCR4 Antibody Treatment Suppresses Metastatic Spread to the Lung of Intratibial Human Osteosarcoma Xenografts In Mice
Clin Exp Metastasis 31(3):339-49, 2014
Pauli C, Fuchs B, Pfirrmann C, Bridge JA, Hofer, S Bode B:
Response of an Aggressive Periosteal Aneurysmal Bone Cyst (ABC) of the Radius to Denosumab Therapy
World J Surg Oncol 12(1): 17, 2014 Doi: 10.1186/1477-7819-12-17
Modaressi K, Giovanoli P, Schneider P, Sulser T, Werner C, Bode B, Fuchs B:
Rezidivierendes Rektumkarzinom: Sakrektomie mit kompletter dorsaler Exenteration
Leading Opinions Orthopedics & Rheumatology 1/14:46-8, 2014
Botter S, Neri D, Fuchs B:
Recent Advances in Osteosarcoma
Curr Opin Pharmacol 16C:15-23, 2014
Datta NR, Puric E, Schneider R, Fuchs B, Bodis S, Weber D:
HYPROSAR: Hyperthermia and Proton Radiotherapy in Soft Tissue Sarcoma
Leading Opinions Hämatologie & Onkologie 2:158-60, 2014
Arlt M, Banke I, Walters D, Berndt K, Strehler E, Born W, Fuchs B:
The Use of LacZ-transduced Tumor Cells Enhances the Sensitivity of Micrometastasis Detection: A Comparative Study of Gemcitabine Treatment Efficacy in the Mouse LM8 Osteosarcoma Cell Model
J Cancer Res Ther 2(6):89-95, 2014
Jentzsch T, Robl B, Husmann K, Bode B, Fuchs B:
Worse Prognosis of Osteosarcoma Patients expressing IGF-1 on a Tissue Microarray
Anticancer Res 34(8):3881-9, 2014
Kumar R, Betz M, Robl, Born W, Fuchs B:
ΔNp63alpha Exerts Its Oncogenic Potential via Transcriptionally Regulating GLI2 in Osteosarcoma Cells
BMC Cancer 14: 559, 2014 (IF 3.319)
Rimann M, Laternser S, Gvozdenovic A, Muff R, Fuchs B, Kelm J, Graf-Hausner U:
An In-vitro Osteosarcoma 3D Microtissue Model for Drug Development
J Biotechnology 189C:129-135, 2014
Jentzsch T, Robl B, Husmann M, Bode B, Fuchs B:
Expression of MSH2 and MSH6 on a Tissue Microarray in Patients with Osteosarcoma
Anticancer Res 34(12):6961-72, 2014
Research and Development in Tumour Surgery: The Importance of Team Work
Swiss Cancer Research Foundation 1:95-99, 2014
Scharl M, Bode B, Rushing E, Knuth A, Rordorf T:
Uncommon case of brain metastasis in a patient with a history of heavy smoking
Current oncology. 2014;21(5):e728-31
Gvozdenovic A, Arlt M, Campanile C, Brennecke P, Husmann K, Li Y, Born W, Muff R, Fuchs B:
CD44 Enhances Tumor Formation and Lung Metastasis in Experimental Osteosarcoma and is an Additional Predictor for Poor Patients' Outcome
J Bone Min Res 28(4):838-47, 2013
Husmann K, Arlt M, Muff R, Langsam B, Bertz J, Born W, Fuchs B:
Matrix Metalloproteinase 1 promotes Tumor Formation and Lung Metastasis in an Intratibial Injection Osteosarcoma Mouse Model
BBA Molecular Basis of Disease 1832(2):347-54, 2013
Jentzsch T, Erschbamer M, Seeli F, Fuchs B:
Extensor Function After Medial Gastrocnemius Flap Reconstruction of the Proximal Tibia
Clin Orthop Rel Res 471(7):2333-9, 2013
Campanile C, Arlt M, Gvozdenovic A, Brennecke P, Sabile A, Honer M, Fischer C, Mueller A, Ametamey S, Krämer S, Schibli R, Born W, Fuchs B:
Characterization of Different Osteosarcoma Phenotypes by PET Imaging in Preclinical Animal Models
J Nuclear Medicine 54(8):1362-8, 2013
Modaressi K, Fuchs B, Bode P, Sutter R, Decurtins M, Weber U:
Osteoblastoma of the Ilium mimicking sacroiliitis
Arthritis Rheum 65(6):1674, 2013
Gozdenovic A, Arlt M, Campanile C, Brennecke P, Husmann K, Born W, Muff R, Fuchs B:
Silencing of CD44 Gene Expression in Human 143-B Osteosarcoma Cells Promotes Metastasis of Intratibial Tumors in SCID Mice
PLosOne 8(4):e60329, 2013
Berndt K, Campanile C, Muff R, Strehler E, Born W, Fuchs B:
Evaluation of Quercetin as a Potential Drug in Osteosarcoma Treatment
Anticancer Res 33(4):1297-306, 2013
Sabile A, Arlt M, Muff R, Bode B, Langsam B, Bertz J, Jentzsch T, Born W, Fuchs B:
Caprin1 promotes Metastasis in an Experimental Animal Model of Osteosarcoma
BBA Molecular Basis of Disease 1832(8):1173-82, 2013
Crivelli-Ochsner S, Bode B, Nussbaumer-Ochsner Y, Fuchs B:
Giant Cell Angioblastoma in an Adult: A Unique Presentation
Rare Tumors 5e27:98-100, 2013
Modaressi K, Studer G, Bode B, Hofer S, Fuchs B:
Knochenmetastasen – Abklärung und Therapie. Schlaglicht Schweizerische Aertzte Zeitung, Frühjahr 2013
Swiss Med Forum 13(2930):571-79, 2013
Wieser K, Modaressi K, Seeli F, Fuchs B:
Autologous Double-Barrel Vascularized Fibular Bone Graft for Arthrodesis of the Shoulder after Tumor Resection
Archives Orthop Traumatol 133(9):1219-24, 2013
Brennecke P, Arlt M, Muff R, Campanile C, Gvozdenovic A, Husmann K, Holzwarth N, Cameroni E, Ehrensperger F, Thelen M, Born W, Fuchs B:
Expression of the Chemokine Receptor CXCR7 in CXCR4-Expressing Human 143B Osteosarcoma Cells Enhances Lung Metastases of Intratibial Xenografts in SCID Mice
PLosOne 8(9):e74045, 2013
Arlt M, Banke I, Bertz J, Mohan R, Muff R, Born W, Fuchs B:
Reduced Latency in the Metastatic Niche Contributes to the More Aggressive Phenotype of LM8 Compared to Dunn Osteosarcoma Cells
Sarcoma 2013; 2013:404962 doi: 10.1155/2013/404962
Wernhart S, Woernle CM, Neidert MC, Bode B, Rushing EJ, Studer G, et al:
A deeply seated brain metastasis from a primary myxofibrosarcoma: case report
Clinical neurology and neurosurgery. 2013;115(10):2296-8
Sydler T, lesser M, Waldern N, Dennler M, Bode-Lesniewska B, Pospischl A, et al:
Malignant peripheral nerve sheath tumour in the nasopharynx of a cow
Schweizer Archiv für Tierheilkunde. 2013;155(11):621-6
Sharma A, Bode B, Studer G, Moch H, Okoniewski M, Knuth A, et al:
Radiotherapy of human sarcoma promotes an intratumoral immune effector signature
Clinical Cancer Research. 2013;19(17):4843-53
Magagna Poveda A, Frontzek K, Bode Lesniewska B, Rushing E:
A 59-year-old woman with a retroauricular tumor
Brain pathology. 2013;23(5):603-4
Farshad M, Bode-Lesniewska B, Min K:
Intraosseous Inflammatory Myofibroblastic Tumor (IMT) of the Twelfth Thoracic Vertebra - Report of a rare case with histological diagnosis and surgical treatment
JBJS Case Connector. 2013
Bode-Lesniewska B, Debiec-Rychter M:
Intimal Sarcoma. In: Fletcher C, Bridge J, Hogendoorn P, Merstens F, editors. WHO Classification of Tumours of Soft Tissue and Bone
Lyon: IARC; 2013. p. 232-3
Steinmann P, Walters D, Arlt M, Banke I, Ziegler U, Langsam B, Arbiser J, Muff R, Born W, Fuchs B:
Antimetastatic Activity of Honokiol in Osteosarcoma
Cancer 118(8):2117-27, 2012
Sabile A, Arlt M, Muff R, Bode B, Langsam B, Bertz J, Jentzsch T, Puskas G, Born W, Fuchs B:
Cyr61 indicates Poor Survival in Osteosarcoma Patients and Promotes Intratibial Xenograft Primary Tumor Growth and Lung Metastasis in Mice
J Bone Mineral Res 27(1):58-67, 2012
Arlt M, Walters D, Banke I, Steinmann P, Puskas G, Bertz J, Rentsch K, Ehrensperger F, Born W, Fuchs B:
The Antineoplastic Antibiotic Taurolidine Promotes Lung and Liver Metastases in Two Syngeneic Osteosarcoma Mouse Models and Exhibits Severe Liver Toxicity
Int J Cancer 131(5):E804-12, 2012 doi: 10.1002/ijc.27378
Betz M, Dumont C, Fuchs B, Exner G:
Epiphyseal Distraction for Joint Preservation in Malignant Metaphyseal Bone Tumors in Children
Clin Orthop Rel Res 470(6):1749-54, 2012
Reidy K, Campanile C, Muff R, Born W, Fuchs B:
mTHPC-mediated Photodynamic Therapy is Effective in the Metastatic Human 143B Osteosarcoma Cells
Photochemistry and Photobiology 88(3):721-7, 2012
Erschbamer M, Bode B, Buck F, Fuchs B:
A Rare Periosteal Diaphyseal Lesions of the Ulna
Open Orthop J 6:8-10, 2012
Modaressi K, Niggli F, Fuchs B:
Strategisches Vorgehen bei Verdacht auf Knochensarkom
Schweizerische Zeitschrift für Onkologie SZO 2: 12-17, 2012
Berndt K, Vogel J, Bühler C, Vogt P, Born W, Fuchs B:
A New Method for Repetitive Drug Infusion into the Femoral Artery of Mice
J Am Assoc Lab Animal Science 51(6):825-31, 2012
Studer G, Bode B, Fuchs B:
Extremitäten-Weichteilsarkom des Erwachsenen: Stellenwert der Radiotherapie
Info @ Onkologie 02:14-17, 2012
Arlt M, Born W, Fuchs B:
Taurolidine: Mode of Administration in Mouse Tumor Models
Int J Cancer 131(5):E1053-4, 2012 doi:10.1002/ijc.27569
Modaressi K, Fuchs B:
Die Chirurgische Behandlung von Sarkomen
Leading Opinions Hämatologie & Onkologie 2:74-76, 2012
Arlt M, Born W, Fuchs B:
Improving Visualization of Lung Metastases by Combining X-Gal Staining of LacZ-tagged Tumor Cells with In-situ Perfusion and Fixation of the Lung Tissue
J Vis Exp (66):e4162, 2012 DOI 10.3791/4162
Muff R, Kumar R, Botter S, Born W, Fuchs B:
Genes Regulated in Metastatic Osteosarcoma: Evaluation by Microarray Analysis in Four Human and Two Mouse Cell Line Systems
Sarcoma 2012; 2012:937506 DOI 10.1155/2012/937506
Kordic H, Bode-Lesniewska B, Pangalu A, Chaloupka K:
Solitary fibrous tumour of the orbit: clinical, radiological, histological findings and differential diagnosis of an uncommon tumour
Klin Monbl Augenheilkd. 2012;229(4):382-6
Kalak N, Steffen T, Collen T, Öhlschlegel C, B B, Tosoni I, et al:
Extraartikuläres Synovialsarkom Rolle der neoadjuvanten Chemotherapie: eine histopathologische Untersuchung
Schweizer Zeitschrift Für Onkologie. 2012;2:23-6
Moderne Konzepte der Pathogenese der Weichgewebetumoren Konsequenzen für die histopathologische Diagnostik
Schweizer Zeitschrift Für Onkologie. 2012
Zwolak P, Kuehnel P, Fuchs B:
Extra-articular Knee Resection for Sarcomas with Preservation of the Extensor Mechanism: Surgical Considerations and Review of Cases
Clin Orthop Rel Res 469:251-256, 2011
Krieg A, Hefti F, Speth B, Guillou L, Jundt J, Exner G, v.Hochstetter A, Cserhati M, Fuchs B, Moushine E, Kaelin A, Klenke F, Siebenrock K:
Synovial Sarcomas usually Metastasize after > five Years: A Multicenter, Retrospective Analysis with Minimum Followup of 10 Years for Survivors
Annals of Oncology 22(2):458-67, 2011
Koch P, Fuchs B, Meyer D, Fucentese S:
Closing Wedge Patellar Osteotomy in Combination with Trochleoplasty
Acta Orthop Belg 77(1):116-121, 2011 (IF 0.401)
Arlt M, Banke I, Walters D, Puskas G, Steinmann P, Muff R, Born W, Fuchs B:
LacZ Transgene Expression in the Subcutaneous Dunn / LM8 Osteosarcoma Mouse Model Allows for the Identification of Micrometastasis
J Orthop Res 29(6):938-46, 2011
Current Trends in Musculoskeletal Oncology
Leading Opinions Orthopädie & Rheumatologie 3:22-24, 2011
Sharma A, Bode B, Wenger RH, Lehmann K, Sartori AA, Moch H, et al:
Gamma-Radiation promotes immunological recognition of cancer cells through increased expression of cancer-testis antigens in vitro and in vivo
PLoS One. 2011;6(11):e28217
Schurr UP, Berdajs DA, Bode B, Dzemali O, Emmer MY, Genoni M:
No association between herpes simplex virus 1 and cardiac myxoma. Swiss Medical Weekly
Sabile AA, Arlt MJ, Muff R, Bode B, Langsam B, Bertz J, et al:
Cyr61 expression in Osteosarcoma indicates poor prognosis and promotes intratibial growth and lung metastasis in mice
J Bone Miner Res. 2011
Ossendorf C, Exner G, Fuchs B:
A New Incision Technique to Reduce Tibiofemoral Mismatch in Rotationplasty
Clin Orthop Rel Res 468:1264-1268, 2010
Cytologic diagnosis of sarcoma
Steinmetz H, Ratten M, Ruess Melzer K, Ohlerth S, Lischer C, Oevermann A, et al:
Clinical course of a malignant peripheral nerve sheath tumor in a Siberian tiger (Panthera tigris altaica)
Journal of veterinary diagnostic investigation. 2010;22(6):970-5
Fuchs B, Hoekzema N, Larson D, Inwards C, Sim F:
Osteosarcoma of the Pelvis: Outcome Analysis of Surgical Treatment
Clin Orthop Rel Res 467(2):510-518, 2009
Yuan J, Ossendorf C, Szatkowski J, Bronk J, Maran A, Yaszemski M, Bolander M, Sarkar G, Fuchs B:
Osteoblastic and Osteolytic Human Osteosarcomas can be studied with a New Xenograft Mouse Model Producing Spontaneous Metastases
Cancer Invest 27(4):435-42, 2009
Hudek R, Schmutz S, Regenfelder F, Fuchs B, Koch P:
Novel Measurement Technique of the Tibial Slope on Conventional MRI
Clin Orthop Rel Res 467:2066-72, 2009
Fuchs B, Born W:
Molecular and Cellular Mechanisms of Osteosarcoma Metastasis: Current Knowledge and Perspectives (Review)
Current Orthopaedic Practice 20(6):593-597, 2009
Halder C, Ossendorf C, Maran A, Yaszemski M, Fuchs B, Sarkar G:
Preferential Expression of the Secreted and the Membrane Forms of Tumor Endothelial Marker 7 Transcripts in Osteosarcoma
Anticancer Res 29(11):4317-22, 2009
Terzic A, Bode B, Gratz KW, Stoeckli SJ:
Prognostic factors for the malignant triton tumor of the head and neck
Head Neck. 2009;31(5):679-88
Tami I, Schibli S, Baldi Balmelli S, Bode-Lesniewska B, Hug U, Giovanoli P:
Glomangiomatosis on the hand. A case report
Handchir Mikrochir Plast Chir. 2009;41(1):52-5
Fritzsche FR, Bode B, Thies S, Donati OF, Schiesser M, Clavien PA, et al:
Intrahepatic sarcoma of the follicular dendritic cells
Bodmer N, Walters D, Fuchs B:
Pemetrexed, a Multitargeted Antifolate Drug, Demonstrates Lower Efficacy in Comparison to Methotrexate against Osteosarcoma Cell Lines
Pediatr Blood Cancer 50(4):905-8, 2008
Husmann K, Muff R, Born W, Bolander M, Sarkar G, Fuchs B:
Cathepsins and Osteosarcoma: Expression Analysis identifies Cathepsin K as a Prognostic Indicator of Metastasis
Mol Carcinog 47:66-73, 2008
Walters D, Steinmann P, Langsam B, Schmutz S, Born W, Fuchs B:
Identification of Potential Chemoresistance Genes in Osteosarcoma
Anticancer Res 28:673-80, 2008
Walters D, Muff R, Langsam B, Born W, Fuchs B:
Cytotoxic Effects of Curcumin on Osteosarcoma Cell Lines
Invest New Drugs 26:289-97, 2008
Fuchs B, Ossendorf C, Leerapun T, Sim F:
Intercalary Segmental Reconstruction for Bone Defects
Europ J Surgical Oncol 34(12):1271-6, 2008
Ossendorf C, Studer G, Bode B, Fuchs B:
Sclerosing Epithelioid Fibrosarcoma: Case Presentation and a Systematic Review
Clin Orthop Rel Res 466:1485-1491, 2008
Strobel K, Exner UE, Stumpe KD, Hany TF, Bode B, Mende K, et al:
The additional value of CT images interpretation in the differential diagnosis of benign vs. malignant primary bone lesions with 18F-FDG-PET/CT
Eur J Nucl Med Mol Imaging. 2008;35(11):2000-8
Reiland Y, Dumont CE, Bode-Lesniewska B, Ulrich Exner G:
Extra-articular en bloc resection of the talocrural and the talocalcaneonavicular joints for primary malignant synovial tumour (myxoinflammatory fibroblastic sarcoma)
Scandinavian journal of plastic and reconstructive surgery and hand surgery / Nordisk plastikkirurgisk forening [and] Nordisk klubb for handkirurgi. 2008;42(4):211-4
Ramseier LE, Dumont CE, Bode-Lesniewska B, Lombriser N, Exner GU:
Results of treatment of malignant soft tissue tumours in the groin
Scandinavian journal of plastic and reconstructive surgery and hand surgery / Nordisk plastikkirurgisk forening [and] Nordisk klubb for handkirurgi. 2008;42(5):241-5
Ossendorf C, Studer GM, Bode B, Fuchs B:
Sclerosing epithelioid fibrosarcoma: case presentation and a systematic review
Clin Orthop Relat Res. 2008;466(6):1485-91
Gaumann A, Strubel G, Bode-Lesniewska B, Schmidtmann I, Kriegsmann J, Kirkpatrick CJ:
The role of tumor vascularisation in benign and malignant cardiovascular neoplasms: a comparison of cardiac myxoma and sarcomas of the pulmonary artery
Oncol Rep. 2008;20(2):309-18
Gaumann A, Bode-Lesniewska B, Zimmermann DR, Fanburg-Smith JC, Kirkpatrick CJ, Hofstadter F, et al:
Exploration of the APC/beta-catenin (WNT) pathway and a histologic classification system for pulmonary artery intimal sarcoma. A study of 18 cases
Virchows Arch. 2008;453(5):473-84
Mueller F, Fuchs B, Kaser B:
Comparative Biology of Human and Canine Osteosarcoma
Anticancer Res 27(1A):155-164, 2007
Walters D, Muff R, Langsam B, Gruber P, Born W, Fuchs B:
Taurolidine: A novel Anti-neoplastic Agent induces Apoptosis of Osteosarcoma Cell Lines
Invest New Drugs 25(4):305-12, 2007
Fuchs B, Mahlum E, Halder C, Maran A, Yaszemski M, Bode B, Bolander M, Sarkar G:
High Expression of Tumor Endothelial Marker 7 is associated with Metastasis and poor Survival of Patients with Osteogenic Sarcoma
Gene 399(2):137-143, 2007
Muff R, Nigg N, Gruber P, Walters D, Born W, Fuchs B:
Altered Morphology, Nuclear Stability and Adhesion of Highly Metastatic Derivatives of Osteoblast-like SaOS-2 Osteosarcoma Cells
Anticancer Res 27(6B): 3973-3979, 2007
Strobel K, Bode B, Lardinois D, Exner U:
PET-positive fibrous dysplasia - a potentially misleading incidental finding in a patient with intimal sarcoma of the pulmonary artery
Skeletal Radiol. 2007
Sheikh R, Bode B, Simovitch R, Exner GU:
Hemangioma of the proximal humerus: bleeding hazard at surgery--a case report
J Shoulder Elbow Surg. 2007;16(1):e11-4
Schreiber-Facklam H, Bode-Lesniewska B, Frigerio S, Flury R:
Primary monophasic synovial sarcoma of the duodenum with SYT/SSX2 type of translocation
Hum Pathol. 2007;38(6):946-9
Schmitt JW, Bode B, Dumont CE:
Free functional gracilis muscle transfer for reconstruction of massive ectopic calcification following a lower extremity fracture: a case report and overview of the literature
Arch Orthop Trauma Surg. 2007
Mica L, Gianom D, Bode B, Jaklin P, Hollinger A:
Rare cause of Dysphagy: Giant Polypoid Esophageal well differentiated Liposarcoma
Case Rep Gastroenterol. 2007;1:7-14
Fuchs B, Mahlum E, Halder C, Maran A, Yaszemski M, Bode B, et al:
High expression of tumor endothelial marker 7 is associated with metastasis and poor survival of patients with osteogenic sarcoma
Bode-Lesniewska B, Frigerio S, Exner U, Abdou MT, Moch H, Zimmermann DR:
Relevance of translocation type in myxoid liposarcoma and identification of a novel EWSR1-DDIT3 fusion
Genes Chromosomes Cancer. 2007;46(11):961-71
Cytologic diagnosis of soft tissue tumors
Srivastava A, Fuchs B, Zhang K, Ruan M, Halder C, Mahlum E, Weber K, Bolander M, Sarkar G:
High WT1 Expression is Associated with poor survival of patients with Osteogenic sarcoma metastasis
Clin Cancer Res 12(14): 4237-4243, 2006
Pfeiffer DF, Bode-Lesniewska B:
Fine needle aspiration biopsy diagnosis of angiosarcoma after breast-conserving therapy for carcinoma supported by use of a cell block and immunohistochemistry
Acta Cytol. 2006;50(5):553-6
Bode B, Frigerio S, Behnke S, Senn B, Odermatt B, Zimmermann DR, et al:
Mutations in the tyrosine kinase domain of the EGFR gene are rare in synovial sarcoma
Mod Pathol. 2006;19(4):541-7
Fuchs B, Trousdale R, Rock M:
Solitary Bony Metastasis from Renal Cell Carcinoma: Significance of Surgical Treatment
Clin Orthop 431:187-192, 2005
Fuchs B, Steinmann S, Bishop A:
Free Vascularized Corticoperiosteal Bone Graft for the Treatment of Persistent Nonunion of the Clavicle
J Shoulder Elbow Surg 14(3):264-268, 2005
Fuchs B, O'Connor M, Padget D, Kaufman K, Sim F:
Arthrodesis of the Shoulder after Tumor Resection
Clin Orthop 436:202-207, 2005
Fuchs B, Dickey I, Yaszemski M, Inwards C, Sim F:
Operative Management of Sacral Chordoma
J Bone Joint Surg 87-Am 10:2211-2216, 2005
Dickey I, Hugate R, Fuchs B, Yaszemski M, Sim F:
Reconstruction after Total Sacrectomy: Early Experience with a New Surgical Technique
Clin Orthop 438:42-50, 2005
Fuchs B, Spinner R, Rock M:
MPNST Malignant Peripheral Nerve Sheath Tumors: An update
J Surg Orthop Adv 14:168-174, 2005
Rudiger HA, Dora C, Bode-Lesniewska B, Exner GU:
Extra-articular resection of the hip with a posterior column-preserving technique for treatment of an intra-articular malignant lesion. A report of two cases
J Bone Joint Surg Am. 2005;87(12):2768-74
Romer M, Bode B, Schuknecht B, Schmid S, Holzmann D:
Solitary fibrous tumor of the orbit-two cases and a review of the literature
Eur Arch Otorhinolaryngol. 2005;262(2):81-8
Min K, Espinosa N, Bode B, Exner GU:
Total sacrectomy and reconstruction with structural allografts for neurofibrosarcoma of the sacrum. A case report
J Bone Joint Surg Am. 2005;87-A(4):864-9
Bode-Lesniewska B, Hodler J, von Hochstetter A, Guillou L, Exner U, Caduff R:
Late solitary bone metastasis of a primary pulmonary synovial sarcoma with SYT-SSX1 translocation type: case report with a long follow-up
Virchows Arch. 2005;446(3):310-5
Fuchs B, Inwards C, Janknecht R:
VEGF expression is Upregulated by EWS-ETS Oncoproteins and Sp1 and may Represent an Independent Predictor of Survival in Ewing's sarcoma
Clin Cancer Res 10:1344-1353, 2004
Chao E, Fuchs B, Rowland C, Illstrup D, Pritchard D, Sim F:
Long-term Results of Segmental Prosthesis Fixation by Extra-Cortical Bone Bridging and Ingrowth
J Bone Joint Surg Am 86:948-955, 2004
Fuchs B, Sim F:
Rotationplasty about the Knee: Surgical Technique and Anatomical Considerations
Clin Anat 17(4):345-353, 2004
Fuchs B, Inwards C, Scully S, Janknecht R:
hTERT is Highly Expressed in Ewing's Sarcoma and Activated by EWS-ETS Oncopoteins
Clin Orthop 426:64-68, 2004
Dickey I, Rose P, Fuchs B, Okuno S, Wold L, Sim F, Scully S:
Dedifferentiated Chondrosarcoma: Updated Ouctomes with Current Treatment Approaches
J Bone Joint Surg 86-Am 11:2412-2418, 2004
Sim F, Fuchs B, Jacofsky D:
Innovations in Musculoskeletal Oncologic Surgery over the Year 2000
Chir Organi Mov 89(3):181-190, 2004
Fuchs B, Knothe U, Hertel R, Ganz R:
Femoral Osteotomy and Iliac Graft Vascularization for Femoral Head Osteonecrosis
Clin Orthop 412:84-93, 2003
Fuchs B, Inwards C, Janknecht R:
Upregulation of the matrix metalloproteinase-gene by the Ewing’s sarcoma associated EWS-ER81 and EWS-Fli1 oncoproteins, c-Jun and p300
FEBS Letters 553:104-108, 2003
Fuchs B, Valenzuela R, Sim F:
Pathologic Fracture as a Complication in the Treatment of Ewing’s Sarcoma
Clin Orthop 415: 25-30, 2003
Fuchs B, Kotajarvi B, Kaufman K, Sim F:
Functional Outcome of Patients with Rotationplasty about the knee
Clin Orthop 415: 52-58, 2003
Fuchs B, Valenzuela R, Arndt C, Petersen I, Sim F:
Ewing's sarcoma and the Development of Secondary Malignancies
Clin Orthop 415: 82-89, 2003
Fuchs B, Valenzuela R, Inwards C, Sim F, Rock M:
Complications in Long-term Survivors of Ewing’s sarcoma
Cancer 98(12):2687-92, 2003
Fuchs B, Yaszemski M, Sim F:
Resection of the Posterior Pelvis and Lumbar Spine for Sarcoma
Clin Orthop 397:12-18, 2002
Todd LT, Yaszemski MJ, Currier BL, Fuchs B, Kim CW, MB.Dekutoski, Sim FH:
Bowel and Bladder Function following Major Sacral Resection
Clin Orthop 397:36-39, 2002
Talac R, Yaszemski MJ, Currier BL, Fuchs B, Dekutoski MB, Kim CW, Sim FH:
Relationship between surgical margins and local recurrence in sarcomas of the spine
Clin Orthop 397:127-32, 2002
Fuchs B, Pritchard D:
Etiology of Osteosarcoma
Clin Orthop 397:40-52, 2002
Fuchs B, O’Connor M, Kaufman K, Padgett D, Sim F:
Iliofemoral arthrodesis and Pseudarthrosis: A functional long-term outcome evaluation
Clin Orthop 397:29-35, 2002
Zhang K, Dion N, Fuchs B, Damron T, Gitelis T, Irwin R, O'Connor M, Schwartz H, Scully S, Rock M, Bolander M, Sarkar G:
The hSEP1 is a novel candidate tumor suppressor gene in osteogenic sarcoma
Gene 298:121-127, 2002
Bode-Lesniewska B, von Hochstetter A, Exner GU, Hodler J:
Gorham-Stout disease of the shoulder girdle and cervico-thoracic spine: fatal course in a 65-year-old woman
Skeletal Radiol. 2002;31(12):724-9
Fuchs B, Davis A, Wunder J, Bell R, Masri B, Isler B, Turcotte R, Rock M:
Sciatic nerve resection in the thigh: A functional evaluation
Clin Orthop 382: 34-41, 2001
Fuchs B, Zhang K, Schabel A, Bolander M, Sarkar G:
Identification of twenty-two candidate genetic markers for osteogenic sarcoma
Gene 278:245-252, 2001
Genoni M, Biraima AM, Bode B, Shan AC, Wilkler MB, Turina MI:
Combined resection and adjuvant therapy improves prognosis of sarcomas of the pulmonary trunk
J Cardiovasc Surg (Torino). 2001;42(6):829-33
Bode-Lesniewska B, Zhao J, Speel EJ, Biraima AM, Turina M, Komminoth P, et al:
Gains of 12q13-14 and overexpression of mdm2 are frequent findings in intimal sarcomas of the pulmonary artery
Virchows Arch. 2001;438(1):57-65
Fuchs B, Zhang K, Bolander M, Sarkar G:
Identification of differentially expressed genes by mutually subtracted RNA fingerprinting
Analytical Biochem Nov 286(1):91-98, 2000
Fuchs B, Zhang K, Bolander M, Sarkar G:
Differential mRNA fingerprinting by preferential amplification of coding sequences
Gene 258:155-163, 2000
Fuchs B, Zhang K, Rock M, Bolander M, Sarkar G:
Repeat cDNA synthesis and RT-PCR with the same source of RNA
Molecular Biotechnology Vol 12:231-235, 1999
Fuchs B, Zhang K, Rock M, Bolander M, Sarkar G:
High temperature cDNA synthesis by AMV reverse transcriptase improves the specificity of PCR
Molecular Biotechnology Vol 12:237-240, 1999
There are always several projects which can be conducted. Everyone -student. resident, sarcoma expert- who wants to contribute is free to address to , Geschäftsstelle SSN for more information.
March 4, 2021
Webinar: Definition of unresectable sarcoma – chemotherapy indications
Prof. Peter Rose, MD, MN, USA
Prof. Michael Yaszemski, MD PhD, MN, USA
May 6, 2021
Webinar: Quality based Health Care and Quality Indicators for Sarcoma Patients
Prof. Bruno Fuchs, Winterthur, SWITZERLAND
July 1, 2021
Webinar: Areas of improvement in sarcomas
Prof. Javier-Martin Broto, Sevilla, SPAIN
September 2, 2021
Webinar: Why did the Announce Trial fail in front line soft-tissue sarcomas treatment: lessons learned
Prof. Axel Le Cesne, Villejuif Cedex, FRANCE
November 4, 2021
Webinar: Assessment of tumor response on imaging
Prof. Axel Le Cesne, Villejuif Cedex, FRANCE
January 7, 2021
Webinar: Immunotherapy for sarcomas
Prof. Jean-Yves Blay, Lyon, FRANCE
October 29, 2020
Webinar: Retroperitoneal sarcoma (surgery, RT)
Prof. Alessandro Gronchi, Milano, ITALY
September 10, 2020
Webinar: How to select sarcoma treatment in 2020 (histology – biology)
Prof. Axel Le Cesne, Villejuif Cedex, FRANCE
January 26, 2019
September 14 - 15, 2017
Prof. Stefan Breitenstein
Prof. Gabriela Studer
Swiss Sarcoma Network
Prof. Bruno Fuchs
Frau Manuela Reich